Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS – Free Report) – Stock analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for shares of Barinthus Biotherapeutics in a note issued to investors on Tuesday, August 25th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.27) for the quarter. HC Wainwright also issued estimates for Barinthus Biotherapeutics’ Q4 2026 earnings at ($0.27) EPS and FY2026 earnings at ($0.93) EPS.
Separately, Weiss Ratings raised Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $4.00.
Barinthus Biotherapeutics Stock Up 7.0%
Barinthus Biotherapeutics stock opened at $0.71 on Thursday. Barinthus Biotherapeutics has a 52-week low of $0.51 and a 52-week high of $1.83. The firm has a market capitalization of $28.86 million, a price-to-earnings ratio of -0.69 and a beta of -0.39. The firm has a 50-day moving average price of $0.62 and a two-hundred day moving average price of $0.63.
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02.
Institutional Investors Weigh In On Barinthus Biotherapeutics
Hedge funds have recently modified their holdings of the stock. Rangeley Capital LLC lifted its stake in Barinthus Biotherapeutics by 88.8% during the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after buying an additional 75,024 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Barinthus Biotherapeutics by 115.8% in the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after acquiring an additional 76,800 shares in the last quarter. Finally, Baird Financial Group Inc. raised its holdings in shares of Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after acquiring an additional 100,000 shares during the period. 25.20% of the stock is owned by hedge funds and other institutional investors.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
See Also
- Five stocks we like better than Barinthus Biotherapeutics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
